Patent Number: 6,428,782

Title: Non-myeloablative tolerogenic treatment

Abstract: The present invention features a method of inducing donor-specific tolerance in a host. Tolerogenic treatments of the present invention may be administered to a host prior to transplantation of donor-derived materials. The tolerogenic treatment involves (1) administering an immunosuppressive agent to a host mammal in a non-myeloablative regimen sufficient to decrease, but not necessarily to eliminate, the host mammal's functional T lymphocyte population; (2) infusing donor antigens from a non-syngeneic donor into the host mammal; (3) eliminating those host T lymphocytes responding to the infused donor antigens using a non-myeloablative dose of lymphocytotoxic or tolerizing agent; and (4) administering donor hematopoietic cells to the host mammal. Donor lymphoid cells used for cell therapy of a host mammal can be depleted of host specific immunological reactivity by methods essentially similar to those use for tolerizing a host mammal prior to transplantation.

Inventors: Slavin; Shimon (Jerusalem, IL), Prigozhina; Tatyana (Rehovot, IL)

Assignee: Hadasit Medical Research Services and Development Ltd.

International Classification: A01K 67/027 (20060101); A61K 35/28 (20060101); A61K 35/12 (20060101); A61K 39/00 (20060101); A61K 038/00 (); C12N 005/08 ()

Expiration Date: 08/06/2019